Mesabi(MSB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MSB Mesabi

Trading 08-28 14:56:37 EDT

24.06

+0.47

+1.99%

High24.18	Low23.63	Vol14.63K
Open23.63	D1 Closing23.59	Amplitude2.33%
Mkt Cap315.67M	Tradable Cap315.42M	Total Shares13.12M
T/O350.82K	T/O Rate0.11%	Tradable Shares13.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MSB","market":"US","secType":"STK","nameCN":"Mesabi","latestPrice":24.06,"timestamp":1787942991526,"preClose":23.59,"halted":0,"volume":14629,"delay":0,"changeRate":0.019923696481559935,"floatShares":13109915,"shares":13120010,"eps":0.863187,"marketStatus":"Trading","change":0.47,"latestTime":"08-28 14:56:37 EDT","open":23.6296,"high":24.1799,"low":23.6296,"amount":350822.73028,"amplitude":0.023328,"askPrice":24.18,"askSize":9,"bidPrice":23.54,"bidSize":200,"shortable":3,"etf":0,"ttmEps":0.863187,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787947200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":23.59,"dividendRate":0.036991,"preHourTrading":{"tag":"盘前","latestPrice":23.69,"preClose":23.59,"latestTime":"05:32 EDT","volume":3,"amount":71.0802,"timestamp":1787909532717,"change":0.1,"changeRate":0.004239,"amplitude":0.000432},"postHourTrading":{"tag":"盘后","latestPrice":23.59,"preClose":23.59,"latestTime":"16:15 EDT","volume":41,"amount":967.19,"timestamp":1787861700110,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.400417,"impliedVol":0.3635,"impliedVolPercentile":0.1833},"requestUrl":"/m/hq/s/MSB/wiki","defaultTab":"wiki","newsList":[{"id":"2661275074","title":"Mesoblast Financial Results and Corporate Update Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275074","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275074?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569200,"startTime":"0","endTime":"0","summary":"NEW YORK, Aug.  24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349620/0/en/mesoblast-financial-results-and-corporate-update-webcast.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","MESO","BK4575","MSC","BK4139","MSB","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661609602","title":"Metals Royalty Raises $165 Million to Fund Additional Mesabi Royalty","url":"https://stock-news.laohu8.com/highlight/detail?id=2661609602","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661609602?lang=en_us&edition=fundamental","pubTime":"2026-08-21 19:58","pubTimestamp":1787313510,"startTime":"0","endTime":"0","summary":"Metals Royalty  said Friday it raised a financing package comprising $140 million of convertible secured notes and a $25 million senior secured term loan.The company said the proceeds will fund the acquisition of an additional 1% royalty in the Mesabi Metallics iron ore project in Minnesota, repay the company's existing term loan and support general corporate purposes.The five-year notes carry an 8% annual coupon and an initial conversion price of about $8.66 per share, representing a 37.5% premium to the $6.30 reference price, while the term loan matures in 24 months with a 12-month extension option, the company said.TMCR also agreed to increase the share consideration payable to Ironclad Royalties for the Mesabi royalty from $7.5 million to $27.5 million.Metals Royalty said the financing and Mesabi royalty acquisition are expected to close concurrently around Aug. 24.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PICK","BK4535","BK4168","BK4006","MSB","TMCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660410575","title":"Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660410575","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660410575?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:50","pubTimestamp":1786927814,"startTime":"0","endTime":"0","summary":"Mesoblast (MESO) announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mesoblast-completes-patient-treatment-in-msb-dr004-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mesoblast-completes-patient-treatment-in-msb-dr004-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","MSB","BBC","BK4006","BK4139","MESO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660105760","title":"Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2660105760","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660105760?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:35","pubTimestamp":1786926900,"startTime":"0","endTime":"0","summary":"NEW YORK, Aug.  16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/17/3345802/0/en/mesoblast-achieves-major-milestone-completing-patient-treatment-in-pivotal-phase-3-trial-for-chronic-low-back-pain.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4546","MSC","MSB","BK4150","BK4575","BK4588","MESO","PRNT","BK4585","BK4170","BK4139","DDD","BK4161","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656339903","title":"Mesabi Trust Receives $1.81 Million in Q2 Royalty Payments from Cleveland-Cliffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2656339903","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656339903?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:31","pubTimestamp":1785529887,"startTime":"0","endTime":"0","summary":"Mesabi Trust receives $1.81 million in Q2 royalty payments from Cleveland-CliffsReceived $1.81 million in royalty payments on July 30, 2026 for the quarter ended June 30, 2026.Base royalty totaled $1.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL2XR3Ht:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB","CLF","BK4585","BK4006","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651481630","title":"Mesabi Trust Declares $0.05 Per Unit Distribution Payable Aug. 20","url":"https://stock-news.laohu8.com/highlight/detail?id=2651481630","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651481630?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:45","pubTimestamp":1784061956,"startTime":"0","endTime":"0","summary":"Mesabi Trust declares $0.05 per unit distribution payable Aug. 20Mesabi Trust declared a $0.05 per unit distribution, payable Aug. 20, 2026 to unitholders of record July 30, 2026.The payout compares w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDL6L0pf8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB","CLF","BK4588","BK4006","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651893314","title":"Press Release: Mesabi Trust Press Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2651893314","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651893314?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:05","pubTimestamp":1784059500,"startTime":"0","endTime":"0","summary":"NEW YORK--(BUSINESS WIRE)--July 14, 2026--Announcement of Mesabi Trust DistributionThe Trustees of Mesabi Trust (NYSE: MSB) declared a distribution of five cents ($0.05) per Unit of Beneficial Interes","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB","GUNR","BK4588","BK4585","BK4006","FLBR","FBZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651143227","title":"The Metals Royalty Company Announces Completion of First Production Blast at Mesabi Metallics","url":"https://stock-news.laohu8.com/highlight/detail?id=2651143227","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651143227?lang=en_us&edition=fundamental","pubTime":"2026-07-14 00:30","pubTimestamp":1783960206,"startTime":"0","endTime":"0","summary":"London, UK, July 13th, 2026, FinanceWire First ore blasted at TMCR’s royalty asset opens the mine’s first ramp toward pellet production...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/the-metals-royalty-company-announces-completion-of-first-production-blast-at-mesabi-metallics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/the-metals-royalty-company-announces-completion-of-first-production-blast-at-mesabi-metallics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PICK","BK4535","BK4006","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651114730","title":"Inter Launches Wearables in the U.S., Taking Banking Beyond the Phone","url":"https://stock-news.laohu8.com/highlight/detail?id=2651114730","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651114730?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:16","pubTimestamp":1783948560,"startTime":"0","endTime":"0","summary":"The Inter Ring and Inter Wristband bring contactless payments to everyday accessories - no phone requiredMIAMI, July  13, 2026  (GLOBE NEWSWIRE) -- For most people, paying for something often follows ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/13/3326239/0/en/Inter-Launches-Wearables-in-the-U-S-Taking-Banking-Beyond-the-Phone.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0353189763.USD","VFH","LU0494093205.USD","FNCL","LU2506952097.USD","LU0964807845.USD","IPAY","BK4548","FDFF","LU0127658192.USD","LU1983260115.SGD","LU1145028129.USD","LU1261432733.SGD","SG9999001424.SGD","LU0256863811.USD","LU1815333072.USD","IE00BFSS7M15.SGD","SGXZ51526630.SGD","LU0823421333.USD","LU1974910355.USD","LU2360106780.USD","LU0823417737.USD","LU2552382132.HKD","IE00BHPRN162.USD","LU2552382215.SGD","IE00BJJMRX11.SGD","LU0234570918.USD","LU2023250504.SGD","LU2506951875.HKD","INTR","LU0957791311.USD","LU0943347566.SGD","BK4581","LU2317271919.USD","LU0985320562.USD","MSB","UYG","IE00BJJMRY28.SGD","LU0823421416.USD","IE00BFSS8Q28.SGD","LU0345769128.USD","IYG","LU0786609619.USD","LU1718418525.SGD","LU2213496289.HKD","LU0006306889.USD","MA","XLF","LU2063271972.USD","LU0640476718.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651116780","title":"Metals Company completes first production blast at Mesabi Metallics","url":"https://stock-news.laohu8.com/highlight/detail?id=2651116780","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651116780?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:35","pubTimestamp":1783942530,"startTime":"0","endTime":"0","summary":"The Metals Royalty Company announced that its portfolio royalty asset, the Mesabi Metallics iron ore project in Nashwauk, Minnesota, has successful...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/metals-company-completes-first-production-blast-at-mesabi-metallics-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/metals-company-completes-first-production-blast-at-mesabi-metallics-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GUNR","BK4535","PICK","BK4006","BK4588","BK4585","FBZ","MSB","FLBR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650157507","title":"Mesoblast (ASX:MSB) Is Up 8.7% After Strong Ryoncil Debut And FDA BLA Milestone - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2650157507","media":"Simply Wall St.","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650157507?lang=en_us&edition=fundamental","pubTime":"2026-07-12 08:28","pubTimestamp":1783816116,"startTime":"0","endTime":"0","summary":"In July 2026, Mesoblast reported that the FDA had accepted its Biologics License Application for rexlemestrocel‑L in preventing life‑threatening gastrointestinal bleeding in end‑stage heart failure patients with LVADs, while the therapy continued to benefit from Orphan Drug and RMAT designations under newly clarified, more flexible FDA guidance for rare diseases.\nSeparately, Mesoblast disclosed record Ryoncil net revenue of US$36,000,000 for the quarter and US$115,000,000 for its first full...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-87-after-strong-ryoncil-debut-and-fda","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-87-after-strong-ryoncil-debut-and-fda","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB","LABU","BK7501","BK4585","MSB.AU","BK7067","BK4006","BK4588","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650390813","title":"Press Release: Ryoncil(r) Delivers Net Revenue of Us$36m for the Fourth Quarter Ended 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2650390813","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650390813?lang=en_us&edition=fundamental","pubTime":"2026-07-10 08:30","pubTimestamp":1783643400,"startTime":"0","endTime":"0","summary":"NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil(R) (remestemcel-","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK4006","MSB","BK7501","BK7508","BK4232","BK4139","BK4575","BK7067","MESO","R","BK4022","MSC","BK4150"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648015660","title":"Why Mesoblast (ASX:MSB) Is Up 9.3% After FDA Accepts Modular BLA Review For Rexlemestrocel-L","url":"https://stock-news.laohu8.com/highlight/detail?id=2648015660","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648015660?lang=en_us&edition=fundamental","pubTime":"2026-07-04 00:35","pubTimestamp":1783096506,"startTime":"0","endTime":"0","summary":"In late June 2026, Mesoblast received a Biologics License Application filing number from the U.S. FDA and requested modular review for rexlemestrocel-L to prevent life-threatening gastrointestinal bleeding in end-stage heart failure patients supported by left ventricular assist devices, building on its Orphan Drug and RMAT designations.\nThe filing comes as new FDA draft guidance reiterates a flexible approach to therapies for rare, high-mortality conditions, potentially aligning closely with...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-up-93-after-fda-accepts-modular-bla","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-up-93-after-fda-accepts-modular-bla","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","LABU","BK7067","BK7501","BK7508","BK4006","MSB.AU","BK4585","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648500937","title":"Treasure Global Recieves Canadian MSB Registration for OXI Wallet Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2648500937","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648500937?lang=en_us&edition=fundamental","pubTime":"2026-07-02 20:51","pubTimestamp":1782996702,"startTime":"0","endTime":"0","summary":"Treasure Global  said Thursday it received access to a Canadian Money Services Business registration, supporting the expansion of its OXI Wallet platform.The company said it plans to add cross-border payments, remittances, foreign exchange, stablecoin settlements, and fiat-to-crypto and crypto-to-fiat conversion services.Treasure Global said it also plans to expand OXI Wallet across the Asia-Pacific region by integrating with regional payment networks, including DuitNow and PayNow.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TGL","BK4006","BK4009","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648957086","title":"Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L?","url":"https://stock-news.laohu8.com/highlight/detail?id=2648957086","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648957086?lang=en_us&edition=fundamental","pubTime":"2026-07-02 13:40","pubTimestamp":1782970812,"startTime":"0","endTime":"0","summary":"Why this FDA milestone matters for Mesoblast\nMesoblast (ASX:MSB) stock is in focus after the US FDA assigned a Biologics License Application filing number for rexlemestrocel-L and accepted a modular review request for patients with LVAD-related risks.\nThis regulatory step, supported by existing Orphan Drug and Regenerative Medicine Advanced Therapy designations, provides formal structure around the approval process for Mesoblast’s late-stage heart failure program and clarifies the path for...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-undervalued-following-fda-progress-for-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-undervalued-following-fda-progress-for-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","PRGS","BK4588","BK4006","BK7501","MSB","BK7067","BK7508","MSB.AU","BK4097","LU2065732104.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648359593","title":"Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs","url":"https://stock-news.laohu8.com/highlight/detail?id=2648359593","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648359593?lang=en_us&edition=fundamental","pubTime":"2026-07-01 08:38","pubTimestamp":1782866280,"startTime":"0","endTime":"0","summary":"NEW YORK, June  30, 2026  (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/01/3320270/0/en/Mesoblast-Receives-BLA-Filing-Number-and-Requests-Modular-Review-for-Rexlemestrocel-L-in-Patients-with-End-Stage-Heart-Failure-and-LVADs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0300736492.USD","BK4150","LU0266512473.USD","BK4575","LU0122376428.USD","MSB","LU0368265418.SGD","IE00BSNM7G36.USD","LU0170899867.USD","BK4585","LU0788109394.HKD","BK4139","BK4588","BK4006","LU0266512127.USD","MESO","MSC","MPC","BK4138","LU0456854461.SGD","LU0300736062.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647735143","title":"OwlTing Group (NASDAQ: OWLS) and Saber Money Open Settlement into India's US$860 Billion Export Economy","url":"https://stock-news.laohu8.com/highlight/detail?id=2647735143","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647735143?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:21","pubTimestamp":1782728460,"startTime":"0","endTime":"0","summary":"Integration with Saber Money brings India rupee payout and Eurozone and UK payment access to OwlPay Harbor, opening a near real-time settlement path into one of the world’s largest cross-border paymen","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/29/3318784/0/en/OwlTing-Group-NASDAQ-OWLS-and-Saber-Money-Open-Settlement-into-India-s-US-860-Billion-Export-Economy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTEC","TQQY","MSB","GPIQ","QQQA","QLD","QQQE","NDX","BK4227","JEPQ","NQmain","BK4006","QQQY","QYLG","NVIW.SI","QQQM","QQQ","TQQQ","PSQ","MNQmain","QDTE","SQQQ","QQQJ","OWLS","TECS","IYW","ONEQ","QID",".IXIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646847290","title":"Press Release: Mesoblast Draws US$50 Million from Five-year Non-dilutive Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2646847290","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646847290?lang=en_us&edition=fundamental","pubTime":"2026-06-25 08:59","pubTimestamp":1782349140,"startTime":"0","endTime":"0","summary":"Optimized capital structure, retiring short-term maturing debtWell-funded for commercial operations and growth pipelineNEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:M","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","MSB.AU","BK4232","BK4575","BK4150","BK4006","BK7501","MSC","R","BK4139","BK4022","MESO","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645965180","title":"Mesoblast (ASX:MSB) Is Up 9.2% After Ryoncil’s Near-US$100m Debut And Revascor FDA Progress – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2645965180","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645965180?lang=en_us&edition=fundamental","pubTime":"2026-06-21 00:29","pubTimestamp":1781972983,"startTime":"0","endTime":"0","summary":"Earlier this week, Mesoblast reported that Ryoncil’s first-year US launch revenue approached about US$100 million, alongside continued FDA engagement on an accelerated-approval pathway and Biologics License Application for heart failure therapy Revascor.\nThis combination of early commercial traction for Ryoncil and active regulatory dialogue on Revascor has sharpened investor focus on Mesoblast’s broader cell therapy pipeline and execution risks.\nWe’ll now examine how Ryoncil’s early US...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-92-after-ryoncils-near-us100m-debut-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-92-after-ryoncils-near-us100m-debut-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4097","PRGS","MSB.AU","LABU","BK7508","BK7501","BK4006","LU2065732104.USD","MSB","BK4585","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643218325","title":"Mesabi Trust Q1 FY27 net income drops 70.05% to $1.09 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2643218325","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643218325?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:17","pubTimestamp":1781295446,"startTime":"0","endTime":"0","summary":"Mesabi Trust net income fell to USD 1.09 million, down from USD 3.63 million a year earlier; net income per unit slid to USD 0.08 from USD 0.28.Total revenues dropped to USD 2.25 million from USD 4.73 million, as royalty income sank to USD 2.08 million from USD 4.35 million.Bonus royalties were absent versus USD 1.78 million a year earlier; base overriding royalties eased to USD 1.89 million from USD 2.43 million.Distributions declared per unit declined to USD 0.24 from USD 0.56; expenses edged up to USD 1.16 million from USD 1.1 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesabi Trust published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system ope","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL1SZR2S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB","BK4006"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mesabi-trust.com","stockEarnings":[{"period":"1week","weight":0.019},{"period":"1month","weight":0.0301},{"period":"3month","weight":-0.1058},{"period":"6month","weight":-0.2232},{"period":"1year","weight":-0.2535},{"period":"ytd","weight":-0.3876}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0408},{"period":"3month","weight":0.0193},{"period":"6month","weight":0.1241},{"period":"1year","weight":0.1925},{"period":"ytd","weight":0.1308}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mesabi Trust, a royalty trust, engages in iron ore mining business in the United States. Mesabi Trust was founded in 1961 and is based in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.565217,"avgChangeRate":0.059897},{"month":2,"riseRate":0.565217,"avgChangeRate":0.031389},{"month":3,"riseRate":0.413043,"avgChangeRate":0.011673},{"month":4,"riseRate":0.382979,"avgChangeRate":-0.006266},{"month":5,"riseRate":0.510638,"avgChangeRate":0.00885},{"month":6,"riseRate":0.361702,"avgChangeRate":-0.010047},{"month":7,"riseRate":0.340426,"avgChangeRate":-0.011775},{"month":8,"riseRate":0.425532,"avgChangeRate":0.00188},{"month":9,"riseRate":0.413043,"avgChangeRate":0.003772},{"month":10,"riseRate":0.391304,"avgChangeRate":-0.005844},{"month":11,"riseRate":0.478261,"avgChangeRate":-0.001259},{"month":12,"riseRate":0.434783,"avgChangeRate":0.025908}],"exchange":"NYSE","name":"Mesabi","nameEN":"Mesabi"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mesabi(MSB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mesabi(MSB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mesabi,MSB,Mesabi股票,Mesabi股票老虎,Mesabi股票老虎国际,Mesabi行情,Mesabi股票行情,Mesabi股价,Mesabi股市,Mesabi股票价格,Mesabi股票交易,Mesabi股票购买,Mesabi股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mesabi(MSB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mesabi(MSB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}